Covalon Technologies
Logotype for Covalon Technologies Ltd

Covalon Technologies (COV) investor relations material

Covalon Technologies Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Covalon Technologies Ltd
Q3 2026 earnings summary27 Aug, 2026

Executive summary

  • Q3 revenue reached $10,041,033 (CAD 10 million), up 20% year-over-year, with growth across all sales channels, led by U.S. vascular access and contamination protection solutions.

  • Gross profit rose 73% to $6,745,607 (CAD 6.7 million), with gross margin improving to 67.2% from 46.5% last year, driven by high-margin U.S. vascular business and favorable inventory adjustments.

  • Net income for Q3 was $2,810,837 (CAD 2.8 million), a significant increase from the prior year; adjusted EBITDA was $3.0 million, more than triple last year.

  • Cash position increased to $19.4 million at quarter-end, up $2.8 million from the previous quarter, with no bank debt.

  • All key financial metrics—revenue, gross profit, gross margin, adjusted gross margin, and adjusted EBITDA—were the highest in any quarter in the past five years.

Financial highlights

  • Q3 gross margin was 67.2%, up from 46.5% last year; adjusted gross margin was 66.4% versus 55.6%.

  • Operating expenses remained stable at $4,018,397 (CAD 4 million), up just 1% year-over-year.

  • Generated $7.4 million in operating cash flow in nine months, up from $3.0 million last year.

  • Paid out $4.1 million in the first-ever dividend and invested over $1 million in capital expenditures.

  • Year-to-date revenue was $25,656,349 (CAD 26 million), up 6% year-over-year, with net income more than doubling to $4 million and EPS rising to $0.15.

Outlook and guidance

  • Management expressed strong optimism for continued growth, citing robust sales momentum, expanding adoption of key products, and a robust pipeline for hospital opportunities.

  • Investments in manufacturing and regulatory submissions are expected to support future efficiency and international expansion.

  • Fiscal 2026 is on track for strong performance, with growth expected to continue into next year and beyond.

  • Focus remains on expanding contamination protection solutions and driving value creation.

  • Management highlights massive further opportunity with existing account penetration and new account acquisition.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Covalon Technologies earnings date

Logotype for Covalon Technologies Ltd
Q4 202610 Dec, 2026
Covalon Technologies
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Covalon Technologies earnings date

Logotype for Covalon Technologies Ltd
Q4 202610 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Covalon Technologies Ltd. is a medical technology company that develops, manufactures, and markets advanced wound care products, infection prevention solutions, and medical devices. The company's product offerings include antimicrobial dressings, collagen-based wound care products, and adhesive technologies designed to reduce infections and improve patient outcomes. Covalon serves healthcare providers, hospitals, and long-term care facilities, with a focus on providing solutions that promote faster healing and reduce the risk of complications in patients. The company operates primarily in North America and internationally, addressing the needs of the healthcare and medical device industries. The company is headquartered in Mississauga, Ontario, Canada, and its shares are listed on the TSX.